ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA

07 Jan 2026 19:12 CET

Issuer

ABIONYX PHARMA

Regulatory News:

Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025:

  • Number of shares: 63,024
  • Cash balance: 250,951.67 €

During the 2nd half of 2025, a total of :

PURCHASE

437,203 shares

1,389,323.53 €

369 transactions

SALE

536,477 shares

1,560,333.66 €

502 transactions

As a reminder, at the half-yearly balance sheet dated June 30, 2025, the following assets were included in the liquidity account:

  • Number of shares: 162,298 shares
  • Cash balance: 86,279.52 €

When the liquidity contract was set up, the following resources were made available:

  • Number of shares: 131,000 shares
  • Cash balance: 40,801.20 €

ANNEX H2 2025

 

Purchases

Sales

ABNX FP

Number of transactions

Number of shares

Capital in EUR

Number of transactions

Number of shares

Capital in EUR

Total

369

437 203

1 389 323,53

502

536 477

1 560 333,66

20250701

1

1

1,19

3

2 902

3 492,92

20250702

1

1

1,21

2

224

271,49

20250703

2

2 271

2 707,06

2

2

2,44

20250704

1

1

1,21

1

1

1,21

20250707

1

1

1,21

1

1

1,21

20250708

1

1

1,21

1

1

1,21

20250709

1

1

1,19

1

1

1,19

20250710

1

1

1,21

1

1

1,21

20250711

1

1

1,21

2

1 781

2 172,81

20250714

1

1

1,22

2

32

39,17

20250715

1

1

1,23

1

1

1,23

20250716

1

1

1,23

1

1

1,23

20250717

1

1

1,23

1

1

1,23

20250718

1

1

1,23

2

2 211

2 746,05

20250721

1

1

1,26

2

153

193,08

20250722

1

1

1,25

1

1

1,25

20250723

1

1

1,26

5

8 691

11 045,44

20250724

1

1

1,30

5

12 291

16 286,42

20250725

3

3 681

4 900,69

4

7 551

10 418,87

20250728

1

1

1,39

11

30 861

44 685,19

20250729

3

4 551

6 939,43

11

23 541

38 883,67

20250730

7

16 231

28 984,31

1

1

1,85

20250731

11

26 661

43 396,07

1

1

1,75

20250801

5

8 061

12 270,79

5

8 409

13 719,53

20250804

1

1

1,63

9

22 381

37 265,25

20250805

3

3 082

5 176,63

5

8 621

15 063,56

20250806

1

1

1,73

4

3 162

5 499,94

20250807

6

13 921

22 958,52

1

1

1,74

20250808

6

11 283

17 654,04

1

1

1,61

20250811

1

1

1,60

6

16 139

26 625,15

20250812

1

1

1,67

1

1

1,67

20250813

1

1

1,82

5

8 561

15 592,26

20250814

2

3 041

5 552,91

6

9 801

18 728,69

20250815

3

4 441

8 081,58

3

2 471

4 694,90

20250818

1

1

1,85

5

7 381

13 761,45

20250819

1

1

1,90

5

6 761

13 001,38

20250820

1

1

1,92

2

1 041

1 994,56

20250821

1

1

1,91

4

4 111

7 922,95

20250822

1

1

1,92

11

16 261

33 277,95

20250825

1

1

2,15

11

12 341

28 080,35

20250826

9

29 511

61 139,20

4

2 261

5 134,54

20250827

1

1

2,06

11

15 911

35 190,61

20250828

1

1

3,00

11

12 281

36 843,00

20250829

3

4 451

12 561,07

11

9 471

29 076,87

20250901

1

1

3,58

11

8 281

30 366,58

20250902

11

21 591

88 354,20

5

2 251

10 356,40

20250903

7

11 071

39 819,29

3

1 321

5 059,59

20250904

1

1

3,67

9

9 931

37 813,67

20250905

6

9 721

35 058,97

2

146

554,77

20250908

10

17 481

58 490,32

1

1

3,67

20250909

2

1 071

3 288,01

3

4 301

15 058,31

20250910

5

4 381

15 945,72

2

1 111

4 210,62

20250911

1

1

3,69

10

16 481

63 688,84

20250912

2

1 741

6 624,56

5

5 471

21 652,16

20250915

1

1

4,05

7

7 691

31 674,55

20250916

2

1 951

7 999,10

1

1

4,10

20250917

3

2 701

10 539,33

1

1

3,93

20250918

5

7 061

26 397,84

4

1 418

5 548,50

20250919

1

1

3,98

4

3 861

15 370,43

20250922

4

4 521

16 592,07

4

3 551

13 974,17

20250923

1

1

3,90

2

741

2 897,30

20250924

2

2 151

8 238,42

5

4 321

17 201,42

20250925

3

2 981

11 542,61

2

701

2 775,91

20250926

8

11 691

42 489,70

1

1

3,80

20250929

1

1

3,65

1

1

3,65

20250930

6

8 666

27 625,95

3

1 801

6 087,45

20251001

1

1

3,30

5

5 201

17 679,60

20251002

4

4 031

14 056,97

1

1

3,57

20251003

1

1

3,50

2

961

3 363,50

20251006

4

3 981

13 425,80

3

1 941

6 793,50

20251007

3

2 571

8 573,54

1

1

3,34

20251008

1

1

3,36

5

6 041

20 796,66

20251009

3

2 661

9 086,46

3

1 901

6 672,66

20251010

4

3 981

13 624,80

1

1

3,50

20251013

1

1

3,31

6

7 491

25 790,01

20251014

4

4 201

14 399,15

1

1

3,45

20251015

1

1

3,36

7

9 231

32 617,96

20251016

2

694

2 415,21

3

1 681

6 014,02

20251017

3

2 941

10 387,78

1

1

3,58

20251020

5

6 851

23 172,65

5

5 071

18 272,75

20251021

6

9 251

29 989,79

1

1

3,39

20251022

1

1

3,60

11

16 811

60 519,60

20251023

4

4 571

16 671,75

5

4 621

17 702,95

20251024

1

1

3,80

10

11 221

44 748,50

20251027

4

3 720

14 789,73

10

8 961

38 919,58

20251028

1

1

4,55

11

9 141

43 405,35

20251029

9

17 141

80 006,34

5

2 491

12 793,24

20251030

7

10 551

45 404,28

1

1

4,48

20251031

5

6 161

25 646,05

5

4 551

20 164,05

20251103

3

2 641

10 780,86

5

4 691

20 122,46

20251104

3

2 791

11 169,73

6

5 701

24 018,23

20251105

6

8 891

35 906,45

1

1

4,15

20251106

1

1

3,93

10

12 201

50 259,43

20251107

3

4 101

17 236,46

5

3 771

16 503,76

20251110

4

4 481

18 568,60

2

681

2 914,60

20251111

1

1

4,18

4

2 941

12 445,78

20251112

7

10 501

42 742,65

5

4 111

18 133,25

20251113

3

2 821

11 148,77

3

1 581

6 434,67

20251114

2

291

1 155,34

4

1 631

6 663,64

20251117

1

1

4,28

5

4 631

19 850,73

20251118

3

2 871

11 949,27

1

1

4,17

20251119

1

1

4,22

3

1 541

6 572,62

20251120

3

2 821

11 769,34

3

1 481

6 361,14

20251121

1

1

4,35

9

9 551

42 161,65

20251124

4

4 901

20 063,60

1

1

4,20

20251125

1

1

4,18

5

4 061

17 465,18

20251126

5

6 881

29 098,30

1

1

4,30

20251127

3

2 224

9 072,46

1

1

4,08

20251128

2

2 111

8 528,48

1

1

4,08

20251201

4

4 241

17 022,46

1

1

4,06

20251202

4

4 071

15 973,93

1

1

4,03

20251203

5

6 181

23 005,50

1

1

3,80

20251204

1

1

3,79

5

5 881

22 765,19

20251205

1

1

3,91

3

1 851

7 265,61

20251208

1

1

3,90

1

1

3,90

20251209

3

2 671

10 208,65

2

891

3 483,75

20251210

4

3 951

14 989,23

1

1

3,83

20251211

4

3 851

14 083,72

1

1

3,72

20251212

4

3 721

13 236,49

2

1 011

3 710,29

20251215

1

1

3,53

2

1 051

3 731,03

20251216

4

3 721

12 713,02

1

1

3,42

20251217

9

12 721

39 905,26

1

1

3,16

20251218

1

1

3,20

6

9 481

31 218,90

20251219

1

1

3,41

6

8 501

29 709,51

20251222

5

5 991

20 522,54

1

1

3,54

20251223

1

1

3,40

4

4 381

15 331,30

20251224

1

1

3,49

3

2 111

7 462,79

20251225

0

0

0,00

0

0

0,00

20251226

0

0

0,00

0

0

0,00

20251229

3

2 591

8 925,20

2

1 011

3 568,80

20251230

2

1 831

6 408,52

5

6 101

22 274,12

20251231

1

1

3,67

6

7 291

27 527,77

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

ABIONYX Pharma
infos@abionyx.com

Source

ABIONYX PHARMA

Provider

BusinessWire

Company Name

ABIONYX PHARMA

ISIN

FR0012616852

Symbol

ABNX

Market

Euronext